Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (AMBER II)

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: July 3, 2013
Last updated: February 18, 2016
Last verified: February 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2015
  Primary Completion Date: November 2015 (Final data collection date for primary outcome measure)